

eventual use in human risk assessment. Therefore, to begin to address these areas the NTP is sponsoring a workshop with the following objectives:

- Solicit comment on a process for selection of appropriate nominated substances to undergo cancer hazard evaluation in genetically modified or "transgenic" models.
- Solicit comment on issues related to the proper interpretation of results of "transgenic" cancer models, the implications of these findings for public health decisions, and the most appropriate interpretive language to describe the results of such studies to the scientific/regulatory communities and the public.

Preliminary Agenda

- 8 a.m. Registration
 8:30 a.m. Introduction and Welcome
 8:45 a.m. Plenary Session
- Overview of Selected Transgenic Models
 - Experience with Transgenic Models in the NTP Bioassay
 - Workshop Charge
 - Public Comment
- 10 a.m. Break
 10:30 a.m. Breakout Groups
- Group 1: Solicit comment on a process for selection of appropriate nominated substances to undergo cancer hazard evaluation in genetically modified or "transgenic" models.
 - Group 2: Solicit comment on issues related to the proper interpretation of results of "transgenic" cancer models, the implications of these findings for public health decisions, and the most appropriate interpretive language to describe the results of such studies to the scientific/regulatory communities and the public.
- Noon Lunch (on your own)
 1:00 p.m. Breakout Groups continued
 2:30 p.m. Break
 3:15 p.m. Plenary Session
- Breakout Group Reports
 - Open Discussion
- 4:30 p.m. Adjourn

As additional details and materials for this workshop become available, they will be posted on the NTP web site (<http://ntp-server.niehs.nih.gov>) or can be obtained by contacting Ms. Diane Spencer, NTP Liaison and Scientific Review Office (T: 919-541-2759, F: 919-541-0295, spencer2@niehs.nih.gov).

Registration and Public Comment

The workshop is open to the public and interested individuals are invited to attend as observers. The number of observers will be limited only by the

space available. Due to space limitations, persons interested in attending are asked to pre-register by contacting Ms. Spencer (contact information above).

The NTP invites public comment and time is set-aside during the morning session for presentation of oral comments. Persons wishing to make oral comment are asked to contact Ms. Spencer in advance of the meeting and provide contact information (name, affiliation, telephone, e-mail, and sponsoring organization, if any); however, registration for oral comments will also be accepted on-site. Observers are also welcome to participate in the open discussion in the afternoon plenary session.

The NTP also welcomes receipt of written comments. If sending written comments, please include contact information (name, affiliation, telephone, e-mail, and sponsoring organization, if any) and send to Dr. Mary S. Wolfe, NTP Executive Secretary (P.O. Box 12233, MD A3-01, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709 or wolfe@niehs.nih.gov) by Friday, February 14, 2003. Any comments received will be provided to invited attendees at the meeting and made available for the public.

Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 03-35 Filed 1-2-03; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists

until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at the following Web sites: <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersch or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
 ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585-429-2264
 Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901-794-5770/888-290-1150
 Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400
 Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513-585-6870, (Formerly: Jewish Hospital of Cincinnati, Inc.)